Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study involves review and analysis of disease activity in patients with rheumatoid arthritis who where treated with either conventional DMARDs (Disease Modifying Antirheumatic Drugs) or Biologics and have two existing, consecutive radiographs (x-ray images) of hand and feet taken as part of routine treatment monitoring within a time interval of 12 to 36 months.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | DMARDs |
| |
| 2 | Biologics |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DMARDs or Biologics | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Joint Status Assessed by Radiographic (Roentgen) Progression | Radiographic progression assessed using Ratingen score with range of 0 = normal joint; 1 = one or more erosions, <20% of the joint surface are destroyed; 2 = 21% to 40% of the joint surface are destroyed; 3 = 41% to 60% of joint surface are destroyed; 4 = 61% to 80% of the joint surface are destroyed; 5 = >80% of the joint surface are destroyed. Total possible score based on 38 joints was 0 to 190; higher scores indicated greater joint destruction. Annualized change in Ratingen score calculated as (total change in Ratingen score / time period between radiograph 1 and 2 [months])*12 months. | Baseline (Day 0) up to 48 months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Without Radiographic Progression | An increase of 4 or more points in the Ratingen score was necessary to detect a difference in radiographic progression. Ratingen score range 0 = normal joint to 5 = >80% of the joint surface are destroyed. Total possible score based on 38 joints was 0 to 190; higher scores indicated greater joint destruction. A decrease of 4 (smallest detectable difference) or more points in total Ratingen score was considered a decrease in erosive damage. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Patients who receive Anakinra, Rituximab or Abatacept
Not provided
Not provided
Not provided
200
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Wyeth is now a wholly owned subsidiary of Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Schmittingheide 20-32 | Munster | 48155 | Denmark |
Participants had been treated according to authorized dosages for disease-modifying anti-rheumatic drug (DMARDs) and biologics in Germany. No investigational product had been provided.
A total of 160 participants were screened and 156 entered this non-randomized retrospective evaluation of conventional systemic therapies and biologics in participants with rheumatoid arthritis in routine practice.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | DMARDS | Participants had received disease-modifying basic Rheumatoid Arthritis (RA) therapy with a conventional anti-rheumatic drug (DMARDS) such as methotrexate, leflunomide, or a combination of these. |
| FG001 | Biologics | Participants had received disease-modifying basic Rheumatoid Arthritis (RA) therapy with a tumor necrosis factor (TNF)-alpha-blocker such as etanercept (Enbrel®), infliximab (Remicade®) or adalimumab (Humira®) - may be administered in combination with a conventional DMARD. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | DMARDS | Participants had received disease-modifying basic Rheumatoid Arthritis (RA) therapy with a conventional anti-rheumatic drug (DMARDS) such as methotrexate, leflunomide, or a combination of these. |
| BG001 | Biologics |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Joint Status Assessed by Radiographic (Roentgen) Progression | Radiographic progression assessed using Ratingen score with range of 0 = normal joint; 1 = one or more erosions, <20% of the joint surface are destroyed; 2 = 21% to 40% of the joint surface are destroyed; 3 = 41% to 60% of joint surface are destroyed; 4 = 61% to 80% of the joint surface are destroyed; 5 = >80% of the joint surface are destroyed. Total possible score based on 38 joints was 0 to 190; higher scores indicated greater joint destruction. Annualized change in Ratingen score calculated as (total change in Ratingen score / time period between radiograph 1 and 2 [months])*12 months. | Evaluable population: all participants who had provided two evaluable, consecutive radiographs of the hands and forefeet, taken at intervals of 12 to 48 months. Since the time period between the first and second radiograph could range between 12 to 48 months, changes in Ratingen score were to be normalized to 1 year. | Posted | Mean | Standard Deviation | scores on a scale | Baseline (Day 0) up to 48 months |
|
Baseline up to 48 months
The same event may appear as both an AE and a SAE. However, what is presented are distinct events. Event may be categorized as serious in 1 subject and as nonserious in another subject, or 1 subject may have experienced both a serious and nonserious event during the study. No safety evaluation was performed nor intended; no events were reported.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | DMARDS | Participants had received disease-modifying basic Rheumatoid Arthritis (RA) therapy with a conventional anti-rheumatic drug (DMARDS) such as methotrexate, leflunomide, or a combination of these. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D018501 | Antirheumatic Agents |
| D001688 | Biological Products |
| ID | Term |
|---|---|
| D045506 | Therapeutic Uses |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D045424 | Complex Mixtures |
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline (Day 0) up to 48 months |
| Number of Participants Without Erosions | Radiographic assessment of no erosions using Ratingen scoring categorized as score of 0=normal joint. | Baseline (Day 0) up to 48 months |
| Change From Baseline in Disease Activity Score Based on 28 Joints (DAS 28) | DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity. | Baseline (Day 0) up to 48 months |
| Change From Baseline in Erythrocyte Sedimentation Rate (ESR) | Erythrocyte Sedimentation Rate measured as millimeters per hour (mm/h). | Baseline (Day 0) up to 48 months |
| Change From Baseline in C-reactive Protein (CRP) | C-reactive protein measured as milligrams per liter (mg/l) | Baseline (Day 0) up to 48 months |
| Number of Participants With Change From Baseline in Rheumatoid Factor (RF) | Rheumatoid Factor measured as a titer and categorized as negative (<1:16 ratio) or positive. A ratio >1:16 indicates a higher level of RF. | Baseline (Day 0) up to 48 months |
| Number of Participants With Laboratory Result for Cyclic Citrullinated Peptide-autoantibody-test (CCP) | Cyclic citrullinated peptide-autoantibody-test measured as Enzyme-linked immunosorbent assay (ELISA units or EU) and categorized as negative (<20 EU) or positive (≥20 up to >60 EU). | Baseline (Day 0) up to 48 months |
Participants had received disease-modifying basic Rheumatoid Arthritis (RA) therapy with a tumor necrosis factor (TNF)-alpha-blocker such as etanercept (Enbrel®), infliximab (Remicade®) or adalimumab (Humira®) - may be administered in combination with a conventional DMARD.
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG000 | DMARDS | Participants had received disease-modifying basic Rheumatoid Arthritis (RA) therapy with a conventional anti-rheumatic drug (DMARDS) such as methotrexate, leflunomide, or a combination of these. |
| OG001 | Biologics | Participants had received disease-modifying basic Rheumatoid Arthritis (RA) therapy with a tumor necrosis factor (TNF)-alpha-blocker such as etanercept (Enbrel®), infliximab (Remicade®) or adalimumab (Humira®) - may be administered in combination with a conventional DMARD. |
|
|
| Secondary | Number of Participants Without Radiographic Progression | An increase of 4 or more points in the Ratingen score was necessary to detect a difference in radiographic progression. Ratingen score range 0 = normal joint to 5 = >80% of the joint surface are destroyed. Total possible score based on 38 joints was 0 to 190; higher scores indicated greater joint destruction. A decrease of 4 (smallest detectable difference) or more points in total Ratingen score was considered a decrease in erosive damage. | Evaluable population | Posted | Number | participants | Baseline (Day 0) up to 48 months |
|
|
|
| Secondary | Number of Participants Without Erosions | Radiographic assessment of no erosions using Ratingen scoring categorized as score of 0=normal joint. | Evaluable population. Ratingen scores were calculated based on radiographic assessment, but score of 0 (no erosions) was not reported separately; data not summarized. | Posted | Number | participants | Baseline (Day 0) up to 48 months |
|
|
| Secondary | Change From Baseline in Disease Activity Score Based on 28 Joints (DAS 28) | DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 >3.2 to 5.1 = moderate to high disease activity. | Evaluable population; (n)=number of participants with analyzable data at observation for DMARDS and Biologics, respectively. | Posted | Mean | Standard Deviation | scores on a scale | Baseline (Day 0) up to 48 months |
|
|
|
| Secondary | Change From Baseline in Erythrocyte Sedimentation Rate (ESR) | Erythrocyte Sedimentation Rate measured as millimeters per hour (mm/h). | Evaluable population; (n)=number of participants with analyzable data at observation for DMARDS and Biologics, respectively. | Posted | Mean | Standard Deviation | mm/h | Baseline (Day 0) up to 48 months |
|
|
|
| Secondary | Change From Baseline in C-reactive Protein (CRP) | C-reactive protein measured as milligrams per liter (mg/l) | Evaluable population; (n)=number of participants with analyzable data at observation for DMARDS and Biologics, respectively. | Posted | Mean | Standard Deviation | mg/l | Baseline (Day 0) up to 48 months |
|
|
|
| Secondary | Number of Participants With Change From Baseline in Rheumatoid Factor (RF) | Rheumatoid Factor measured as a titer and categorized as negative (<1:16 ratio) or positive. A ratio >1:16 indicates a higher level of RF. | Evaluable population; (n)=number of participants with analyzable data at observation for Positive or Negative status for DMARDS and Biologics, respectively. | Posted | Number | participants | Baseline (Day 0) up to 48 months |
|
|
|
| Secondary | Number of Participants With Laboratory Result for Cyclic Citrullinated Peptide-autoantibody-test (CCP) | Cyclic citrullinated peptide-autoantibody-test measured as Enzyme-linked immunosorbent assay (ELISA units or EU) and categorized as negative (<20 EU) or positive (≥20 up to >60 EU). | Evaluable population; N=number of participants with evaluable data for CCP. CCP value as a laboratory diagnostic marker was collected within the complete timeframe and was documented only once; calculation for change in value not applicable. | Posted | Number | participants | Baseline (Day 0) up to 48 months |
|
|
|
| 0 |
| 92 |
| 0 |
| 92 |
| EG001 | Biologics | Participants had received disease-modifying basic Rheumatoid Arthritis (RA) therapy with a tumor necrosis factor (TNF)-alpha-blocker such as etanercept (Enbrel®), infliximab (Remicade®) or adalimumab (Humira®) - may be administered in combination with a conventional DMARD. | 0 | 65 | 0 | 65 |
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| Positive RF at second radiograph (n=85, 61) |
|
| Negative RF at second radiograph |
|